Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC
July 4th 2016
An ongoing phase II, four-cohort trial involving
capmatinib (INC280), an oral MET inhibitor,
will determine the clinical activity of the agent
in pretreated patients with advanced non-small cell lung cancer
who have undergone one or two lines of therapy.